Comparison of Ease of Use and Acceptability of Intranasal and Injectable Glucagon Among Providers Administering it to Children or Adolescents With Type 1 Diabetes (BETTER-ING)

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

September 22, 2022

Study Completion Date

September 22, 2022

Conditions
Diabetes Mellitus, Type 1Hypoglycemia
Interventions
BEHAVIORAL

Videos

A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.

BEHAVIORAL

Simulation

An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.

BEHAVIORAL

Interview

At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.

Trial Locations (1)

G1V 4G2

Centre de recherche du CHU de Québec - Université Laval, Québec

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

CHU de Quebec-Universite Laval

OTHER